Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited

被引:14
|
作者
Spencer, K [1 ]
机构
[1] Harold Wood Hosp, Dept Clin Biochem, Endocrine Unit, Romford RM3 0BE, Essex, England
关键词
nuchal translucency; free beta-hCG; PAPP-A; trisomy; 21; counselling; prenatal screening;
D O I
10.1002/pd.430
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objectives To assess the level of correlation of first trimester biochemical and biophysical markers of Down syndrome between different pregnancies in the same individual. To assess the impact that between pregnancy biological variability has on the likelihood that women who are at increased risk in a first pregnancy being also at increased risk in a subsequent pregnancy. Methods During a three period women attending the OSCAR clinic at Harold Wood Hospital have had the opportunity to have first trimester screening for Down syndrome and other aneuploidies using the maternal serum biochemical markers free beta-human chorionic gonadotrophin (hCG) and pregnancy associated plasma protein-A (PAPP-A) in conjunction with fetal nuchal translucency (NT) thickness and maternal age. Of the 11 1105 women undergoing such screening, the computer records were examined for women who had more than one pregnancy. The results from 1002 women with two normal singleton pregnancies were available for analysis. Marker correlations (as MoM) were established between the pregnancies and the proportion of women likely to be at increased risk in each pregnancy estimated, as was the likelihood of women being at increased risk in both pregnancies. Results For fetal NT there was no correlation between NT MoM in the first and second pregnancy (r = 0.0959, p > 0.10). For maternal serum free beta-hCG MoM a significant correlation was found (r = 0.3976, p < 0.001), as was also found for PAPP-A MoM (r = 0.4371, p < 0.001). Conclusion The implication for such between pregnancy marker association is that women who have an increased risk of Down syndrome in one pregnancy are two or three times more likely to repeat this event in their next pregnancy. This information may be useful in counselling women when undergoing first trimester screening in a subsequent pregnancy. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:874 / 876
页数:3
相关论文
共 47 条
  • [41] Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation
    Herraiz, I.
    Lopez-Jimenez, E. A.
    Garcia-Burguillo, A.
    Nieto, O.
    Villar, O. P.
    Escribano, D.
    Galindo, A.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2009, 33 (05) : 518 - 523
  • [42] Comparing outcomes and costs between contingent and combined first-trimester screening strategies for Down's syndrome
    Martin, I.
    Gibert, M. J.
    Aulesa, C.
    Alsina, M.
    Casals, E.
    Bauca, J. M.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 189 : 13 - 18
  • [43] Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study
    Audibert, F
    Dommergues, M
    Benattar, C
    Taieb, J
    Thalabard, JC
    Frydman, R
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2001, 18 (01) : 26 - 31
  • [44] Additive effect of factors related to assisted conception on the reduction of maternal serum pregnancy-associated plasmaprotein A concentrations and the increased false-positive rates in first-trimester Down syndrome screening
    Bellver, Jose
    Casanova, Cristina
    Garrido, Nicolas
    Lara, Coral
    Remohi, Jose
    Pellicer, Antonio
    Serra, Vicente
    FERTILITY AND STERILITY, 2013, 100 (05) : 1314 - +
  • [45] Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies
    Wulff, C. B.
    Gerds, T. A.
    Rode, L.
    Ekelund, C. K.
    Petersen, O. B.
    Tabor, A.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2016, 47 (01) : 38 - 44
  • [46] Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access® platform: suitability for use in first trimester Down's syndrome screening
    Lambert-Messerlian, Geralyn
    Palomaki, Glenn E.
    Canick, Jacob A.
    JOURNAL OF MEDICAL SCREENING, 2010, 17 (03) : 109 - 113
  • [47] First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow
    Abele, Harald
    Wagner, Philipp
    Sonek, Jiri
    Hoopmann, Markus
    Brucker, Sara
    Artunc-Ulkumen, Burcu
    Kagan, Karl Oliver
    PRENATAL DIAGNOSIS, 2015, 35 (12) : 1182 - 1186